- Home
- OPBK vs PBYI Comparison
OPBK vs PBYI Comparison
Compare OPBK & PBYI Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- OPBK
- PBYI
- Stock Information
- Founded
- OPBK 2005
- PBYI 2010
- Country
- OPBK United States
- PBYI United States
- Employees
- OPBK N/A
- PBYI N/A
- Industry
- OPBK Major Banks
- PBYI Biotechnology: Pharmaceutical Preparations
- Sector
- OPBK Finance
- PBYI Health Care
- Exchange
- OPBK Nasdaq
- PBYI Nasdaq
- Market Cap
- OPBK 188.6M
- PBYI 167.3M
- IPO Year
- OPBK 2018
- PBYI N/A
- Fundamental
- Price
- OPBK $12.06
- PBYI $3.31
- Analyst Decision
- OPBK Hold
- PBYI Strong Buy
- Analyst Count
- OPBK 1
- PBYI 1
- Target Price
- OPBK $18.00
- PBYI $7.00
- AVG Volume (30 Days)
- OPBK 62.2K
- PBYI 354.2K
- Earning Date
- OPBK 07-24-2025
- PBYI 07-31-2025
- Dividend Yield
- OPBK 3.98%
- PBYI N/A
- EPS Growth
- OPBK 0.92
- PBYI 143.51
- EPS
- OPBK 1.42
- PBYI 0.77
- Revenue
- OPBK $81,356,000.00
- PBYI $232,709,000.00
- Revenue This Year
- OPBK $19.87
- PBYI N/A
- Revenue Next Year
- OPBK $10.60
- PBYI N/A
- P/E Ratio
- OPBK $8.50
- PBYI $4.34
- Revenue Growth
- OPBK 4.15
- PBYI 2.68
- 52 Week Low
- OPBK $9.30
- PBYI $2.23
- 52 Week High
- OPBK $18.57
- PBYI $4.13
- Technical
- Relative Strength Index (RSI)
- OPBK 47.27
- PBYI 47.57
- Support Level
- OPBK $11.52
- PBYI $3.34
- Resistance Level
- OPBK $11.94
- PBYI $3.39
- Average True Range (ATR)
- OPBK 0.34
- PBYI 0.16
- MACD
- OPBK -0.00
- PBYI -0.04
- Stochastic Oscillator
- OPBK 43.90
- PBYI 19.05
About OPBK OP Bancorp
OP Bancorp is engaged in the general commercial banking business in Los Angeles, Orange, and Santa Clara Counties, California, Carrollton, Texas, and Las Vegas, Nevada. The Bank is focused on serving the banking needs of small- and medium-sized businesses, professionals, and residents with a particular emphasis on Korean and other ethnic minority communities. It operates with eleven full branches.
About PBYI Puma Biotechnology Inc
Puma Biotechnology Inc is a biopharmaceutical company that develops and commercializes inventive products to enhance cancer care and improve treatment outcomes for patients. It is currently commercializing NERLYNX, an oral version of neratinib, for the treatment of HER2-positive breast cancer. Also it develops alisertib. Alisertib is a selective, small-molecule inhibitor of aurora kinase A that is designed to disrupt mitosis leading to apoptosis of rapidly proliferating tumor cells that are dependent on aurora kinase A.